The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co
British Journal of Dermatology2015Vol. 174(2), pp. 296–304
Citations Over TimeTop 1% of 2015 papers
O. Nemoto, M. Furue, Hidemi Nakagawa, Masanari Shiramoto, Ryuzo Hanada, Shunji Matsuki, Shuhei Imayama, Mai Kato, I. Hasebe, Kiyoto Taira, Masakazu Yamamoto, Ryosuke Mihara, Kenji Kabashima, Thomas Ruzicka, Jon M. Hanifin, Yoshito Kumagai
Abstract
A single subcutaneous administration of CIM331 was well tolerated in healthy volunteers and patients with AD. It decreased pruritus, sleep disturbance and topical use of hydrocortisone. CIM331 may become a novel therapeutic option for AD by inhibiting IL-31.
Related Papers
- → Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis(2021)15 cited
- → Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients(2024)8 cited
- → Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice(2016)6 cited
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- → Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”(2021)